EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patterns of Comorbidities in Lung Cancer Patients and Survival

Alessandra Buja iD, Marcello Di Pumpo iD, Massimo Rugge, Manuel Zorzi iD, Federico Rea, Ilaria Pantaleo iD, Giovanna Scroccaro, Pierfranco Conte iD, Leonardo Rigon iD, Giorgio Arcara iD, Giulia Pasello, Valentina Guarneri und 1 weitere

Cancers · 06.05.2025 · 17 (9) · 1577

DOI: 10.3390/cancers17091577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 06.05.2025. Verfasst von Alessandra Buja und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padova, 35128 Padova, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordinamento Regionale per le Attività Oncologiche (CRAO);, Fondazione Periplo, Coordinamento Regionale per le Attività Oncologiche (CRAO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Comorbidities affect diagnosis and treatments in cancer patients. This study explores the prevalence and patterns of comorbidities in non-small cell lung cancer (NSCLC) patients and their association with survival. Materials and Methods: This retrospective population-based cohort study included 1674 incident NSCLC patients. Comorbidities were classified based on the ICD-9-CM system, with 13 disease categories analyzed. Patients with more than two comorbidities were classified into three mutually exclusive and exhaustive latent classes (Latent Class Analysis [LCA]). The optimal number of latent classes was determined by applying the Akaike Information Criterion. Cox regression models were run to assess overall and cancer-specific mortality, adjusting for the comorbidity groups, sex, age, and stage at diagnosis.

Results

In 1674 NSCLC patients, the most prevalent medical conditions were respiratory (35.8%) and cardiovascular (33.5%). The Cox regression showed that even one comorbidity is associated with an increased hazard of overall mortality (HR = 1.33, 95%CI: 1.11–1.59, p = 0.002). LCA-derived Class-1 (cardiovascular-respiratory and endocrine) reported HR = 1.74 (95%CI: 1.39–2.17, p < 0.001), Class-2 (multi-organ) HR = 1.44 (95%CI: 1.18–1.77, p < 0.001), and Class-3 (socio-multifactorial-neuro) HR = 1.62 (95%CI: 1.36–1.93, p < 0.001). Instead, in patients with one comorbidity, NSCLC-specific mortality showed no significant trend towards increased risk (HR = 1.17, 95%CI: 1.00–1.43, p = 0.114). Significant associations emerged between NSCLC-specific mortality and LCA-classes: Class-1: HR = 1.49 (95%CI: 1.20–1.91, p = 0.001); Class-2 HR = 1.25 (95%CI: 1.0–1.57 p = 0.048); and Class-3: HR = 1.23 (95%CI: 1.00–1.48, p = 0.035).

Conclusions

The adverse impact of comorbidities on NSCLC-specific mortality requires their inclusion as risk factors in cancer treatment and prognosis.

Schlagwörter

Stichwörter der Autor:innen

comorbidityepidemiologylung cancerprognosissurvival

Autor:innen und Institutionen

  • Department of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padova, 35128 Padova, Italy.
  • Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Department of Prevention, AULSS6 Euganea, 35100 Padova, Italy.
  • Department of Medicine DIMED-Pathology Unit University of Padova, 35100 Padova, Italy.
  • Veneto Tumor Registry (RTV), Azienda Zero, Passaggio Luigi Gaudenzio, Padova 1, 35131 Padova, Italy.
  • Coordinamento Regionale per le Attività Oncologiche (CRAO), Regione Veneto, 30100 Venezia, Italy.

ORCID-Profile: Alessandra Buja, Marcello Di Pumpo, Manuel Zorzi, Ilaria Pantaleo, Pierfranco Conte, Leonardo Rigon, Giorgio Arcara

Förderung

  • Coordinamento Regionale per le Attività Oncologiche (CRAO);
  • Fondazione Periplo
  • Coordinamento Regionale per le Attività Oncologiche (CRAO)

Zitieren

APA

Buja, A., Di Pumpo, M., Rugge, M., Zorzi, M., Rea, F., Pantaleo, I., Scroccaro, G., Conte, P., Rigon, L., Arcara, G., Pasello, G., Guarneri, V., & Rete Oncologica Veneta and Periplo Foundation (2025). Patterns of Comorbidities in Lung Cancer Patients and Survival. Cancers, 17(9), 1577. https://doi.org/10.3390/cancers17091577

Vancouver

Buja A, Di Pumpo M, Rugge M, Zorzi M, Rea F, Pantaleo I, et al. Patterns of Comorbidities in Lung Cancer Patients and Survival. Cancers. 2025;17(9):1577. doi:10.3390/cancers17091577

BibTeX
@article{Buja2025,
  author = {Buja, Alessandra and Di Pumpo, Marcello and Rugge, Massimo and Zorzi, Manuel and Rea, Federico and Pantaleo, Ilaria and Scroccaro, Giovanna and Conte, Pierfranco and Rigon, Leonardo and Arcara, Giorgio and Pasello, Giulia and Guarneri, Valentina and Rete Oncologica Veneta and Periplo Foundation, Rete Oncologica Veneta and Periplo Foundation},
  title = {Patterns of Comorbidities in Lung Cancer Patients and Survival},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1577},
  doi = {10.3390/cancers17091577}
}
Kostenlos starten →